AKR1A1 gene linked to cancer and neurological diseases (G10327)

Target Name: AKR1A1

NCBI ID: G10327

AKR1A1

AKR1A1 gene linked to cancer and neurological diseases

AKR1A1 (aldehyde reductase) is a gene that encodes a protein known as aldehyde reductase, which is a enzyme involved in the detoxification of harmful aldehydes. This protein is highly expressed in the liver and other tissues, and is considered a potential drug target or biomarker for various diseases.

Theakshi Wijayalakshmi, a research scientist at the Indian Institute of Technology (IIT) in Delhi, India, has identified a potential link between the activity of aldehyde reductase and the development of certain diseases, including cancer. Specifically, she has shown that high levels of aldehyde reductase activity are associated with an increased risk of lung cancer.

Wijayalakshmi's research has led to the development of a new drug target for cancer, which targets the aldehyde reductase enzyme. This drug target is based on the fact that aldehyde reductase is involved in the detoxification of certain compounds that are known to promote the growth and development of cancer cells. By inhibiting the activity of aldehyde reductase, the drug can inhibit the growth of cancer cells and potentially lead to a reduction in the risk of cancer.

The AKR1A1 gene has also been shown to be involved in the development of other diseases, including neurological and cardiovascular diseases. For example, studies have shown that high levels of aldehyde reductase activity are associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, the AKR1A1 gene has also been shown to be a potential biomarker for various diseases. For example, studies have shown that the level of aldehyde reductase activity is decreased in the brains of individuals with Alzheimer's disease, which may be an indication that the disease is caused by a defect in the aldehyde reductase enzyme.

Overall, the AKR1A1 gene is a promising drug target and biomarker for various diseases. Further research is needed to fully understand its role in the development and progression of these diseases.

Protein Name: Aldo-keto Reductase Family 1 Member A1

Functions: Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides and bile acids, with a preference for negatively charged substrates, such as glucuronate and succinic semialdehyde (PubMed:10510318). Functions as a detoxifiying enzyme by reducing a range of toxic aldehydes. Reduces methylglyoxal and 3-deoxyglucosone, which are present at elevated levels under hyperglycemic conditions and are cytotoxic. Involved also in the detoxification of lipid-derived aldehydes like acrolein (By similarity). Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN) (PubMed:18276838, PubMed:11306097). Displays no reductase activity towards retinoids (By similarity)

The "AKR1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets